Finding new treatments for kidney transplant rejection
Official title: Computational Drug Repositioning for Antibody Mediated Renal Allograft Rejection
Funded at University of California, San Francisco · NIH-11126715 · Data updated 2026-11-12
This study is looking for better ways to treat kidney transplant patients who are experiencing antibody-mediated rejection by finding new uses for existing medications based on their unique gene profiles.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 28, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $814,298 |
| NIH project number | 5R01AI180118-02 |
| Project ID | NIH-11126715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are kidney transplant recipients experiencing antibody-mediated rejection.
✕Less likely to help
Patients who have not undergone kidney transplantation or those without antibody-mediated rejection may not benefit from this research.
What this research studies
This research focuses on improving treatments for antibody-mediated rejection (ABMR) in kidney transplant patients. By analyzing gene expression profiles from kidney biopsies, the team aims to identify existing drugs that could be repurposed to treat this condition. The approach involves using advanced computational methods to match drug candidates with the specific molecular characteristics of ABMR. Patients may benefit from more effective therapies tailored to their unique rejection profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for kidney transplant rejection, improving graft survival rates.
How similar studies have gone: Previous research has shown promise in using computational methods for drug repurposing, indicating potential success for this approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Sarwal, Minnie M — University of California, San Francisco
- Study coordinator: Sarwal, Minnie M
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.